ADXN Addex Therapeutics Ltd

16

Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]

CH | NASDAQ | Stock

Price
$1.06
Increased by +1.92%
Dollar Volume
156.87 K
ADR%
9.21
Market Cap.
20.38 M
Shares Float
4.02 M
Shares Outstanding
19.22 M
Beta
1.52
Price / Earnings
-0.32
BPR
9.81
20D Range
0.60 1.11
50D Range
0.55 1.11
200D Range
0.55 5.45
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 4, 21 -0.72 -0.72
Aug 5, 21 -0.77 -0.65
Decreased by -18.46%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 409.42 K
Decreased by -39.97%
 -4.11 M
Decreased by -14.16%
Decreased by -1.00 K%
Decreased by -90.16%
Jun 30, 22 183.35 K
Decreased by -81.53%
 -7.22 M
Decreased by -53.97%
Decreased by -3.94 K%
Decreased by -733.50%
Mar 31, 22 237.24 K
Decreased by -71.90%
 -5.82 M
Decreased by -120.63%
Decreased by -2.45 K%
Decreased by -685.12%
Dec 31, 21 397.49 K
Decreased by -78.17%
 -4.42 M
Decreased by -108.20%
Decreased by -1.11 K%
Decreased by -853.64%
Sep 30, 21 682.00 K
Increased by +2.40 K%
 -3.60 M
Decreased by -8.61%
Decreased by -527.59%
Increased by +95.66%
Jun 30, 21 992.60 K
Increased by +15.31%
 -4.69 M
Decreased by -50.58%
Decreased by -472.51%
Decreased by -30.58%
Mar 31, 21 844.22 K
Decreased by -6.62%
 -2.64 M
Increased by +38.70%
Decreased by -312.67%
Increased by +34.35%
Dec 31, 20 1.82 M
Increased by +75.04%
 -2.12 M
Increased by +41.86%
Decreased by -116.71%
Increased by +66.78%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.